Stockscreener 앱 받기
6.07
2.19%
0.13
시장 영업 전:
6.05
-0.02
-0.33%
전일 마감가:
$5.94
열려 있는:
$6.03
하루 거래량:
2.28M
Relative Volume:
1.11
시가총액:
$1.01B
수익:
$246.03M
순이익/손실:
$-32.00M
주가수익비율:
-28.56
EPS:
-0.2125
순현금흐름:
$-16.78M
1주 성능:
-8.86%
1개월 성능:
-14.27%
6개월 성능:
-23.07%
1년 성능:
+61.87%
1일 변동 폭
$5.8609
$6.135
1주일 범위
$5.73
$7.12
52주 변동 폭
$3.65
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.07 | 985.59M | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-08-12 | 재개 | H.C. Wainwright | Buy |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Decoding Xeris Biopharma Holdings Inc (XERS): A Strategic SWOT Insight - GuruFocus
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock - MarketBeat
Biopharma Appears a Safe Bet Now, So I'm Adding Two Names - TheStreet Pro
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
HC Wainwright Predicts Xeris Biopharma Q2 Earnings - MarketBeat
XERS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xeris Biopharma Balances New Profitability With Recorlev Patent Battles - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript - Insider Monkey
XERS Earnings History & Surprises | EPS & Revenue Results | XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) - ChartMill
Xeris Biopharma Holdings, Inc.Common Stock (NQ: XERS - The Chronicle-Journal
Xeris Biopharma Q4 2025 Earnings Call Transcript - MarketBeat
Xeris Biopharma Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results - MarketBeat
Beth Hecht 10b5-1 sales reported for XERS (NASDAQ: XERS) - Stock Titan
XERS: Achieved first annual net profit and 43.7% revenue growth, led by Recorlev's strong performance - TradingView
Xeris Biopharma (NASDAQ: XERS) outlines endocrine and neuro focus - Stock Titan
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highli - GuruFocus
Today's Analyst Update: XERS Rating Reiterated at Buy by HC Wain - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Receives Buy Rating from HC Wainwright - MarketBeat
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Shares Gap UpHere's What Happened - MarketBeat
Earnings call transcript: Xeris Biopharma’s Q4 2025 earnings beat estimates, stock surges - Investing.com Australia
Xeris Biopharma Q4 Earnings Call Highlights - Yahoo Finance
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
XERS Projects Strong Growth for FY26 with Significant Revenue In - GuruFocus
Xeris (XERS) Sees Strong Q4 Revenue Growth - GuruFocus
(XERS) Xeris Biopharma Expects 2026 Total Revenue Range $375M to $390M, vs. FactSet Est of $368M - marketscreener.com
Earnings Flash (XERS) Xeris Biopharma Holdings, Inc. Reports Q4 Revenue $85.8M, vs. FactSet Est of $82.2M - marketscreener.com
Xeris Bi - Bitget
Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance - Investing.com
Xeris Biopharma: Q4 Earnings Snapshot - marketscreener.com
Xeris Biopharma Reports Record Performance for Q4 and Full Year 2025 - TradingView
XERS: Record 2025 revenue and profitability set the stage for over 30% growth in 2026 - TradingView
Record 2025 results as Xeris Biopharma (XERS) guides for 30%+ 2026 growth - Stock Titan
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance - Business Wire
A Look At Xeris Biopharma Holdings (XERS) Valuation As It Fights To Protect Recorlev Exclusivity - Yahoo Finance
Xeris Biopharma Holdings (XERS) Is Down 7.4% After Suing to Block Recorlev Generics Until 2040 - Sahm
Xeris Biopharma (NASDAQ:XERS) Trading Down 8.3%Should You Sell? - MarketBeat
Why Are Shares Of Xeris Biopharma Falling Friday? - Benzinga
Xeris Biopharma Holdings Enters Oversold Territory (XERS) - Nasdaq
Xeris Pharmaceuticals (XERS) Set to Announce Q4 Earnings with St - GuruFocus
A Peek at Xeris Biopharma Holdings's Future Earnings - Benzinga
Pullback Watch: Can Xeris Biopharma Holdings Inc keep up with sector leadersJuly 2025 PreEarnings & Low Volatility Stock Suggestions - baoquankhu1.vn
Xeris Biopharma Sues Torrent Pharmaceuticals, Somerset Therapeutics Over Recorlev Patents - marketscreener.com
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unveiling a 65% Potential Upside for Investors - DirectorsTalk Interviews
Xeris Biopharma subsidiaries file Recorlev patent infringement lawsuit - marketscreener.com
Xeris Biopharma (XERS) Sues Over Recorlev Patent Dispute - GuruFocus
[8-K] Xeris Biopharma Holdings, Inc. Reports Material Event | XERS SEC FilingForm 8-K - Stock Titan
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):